

HHV-6 Quantitative Real-time DNA PCR

Test ID	6500 HHV-6 Real-time qPCR
Clinical Utility	HHV-6 reactivation can cause fever, rash, hepatitis, encephalitis, pneumonitis, and delay or suppression of bone marrow engraftment (HSCT) and/or increased risk of CMV infection (HSCT or SOT). Bone marrow suppression by HHV-6 is often confused with rejection in an HSCT patient. Quantitative HHV-6 DNA PCR can be used for early detection of a primary infection, tracking the course of infection, and monitoring response to treatment.
Procedure	Extraction of HHV-6 viral DNA from plasma, bone marrow, other biological fluids, or tissues followed by amplification and detection using real-time, quantitative PCR. An internal control is added to ensure the extraction was performed correctly and the PCR reaction was not inhibited.
Specimens	Whole Blood: 3-5 ml submitted in an EDTA tube; ship ambient. CSF: 1 ml fluid frozen; submitted in a sterile, leakproof tube; ship on dry ice. Other: Please inquire.
Specificity	Detects both Type A and Type B in one assay. The primers and probes used in this assay are specific for known strains of HHV-6 based on similarity search algorithms. Additionally, no cross reactivity was detected when tested against adenoviruses, BKV, CMV, EBV, HSV-1, HSV-2, HHV-7, HHV-8, JCV, parvovirus B19, SV-40, and VZV.
Assay Range	100 copies/ml to 1×10^{10} copies/ml
Turnaround Time	Within 24 hours of receiving specimen

PCR tests are performed pursuant to a license agreement with Roche Molecular Systems, Inc.

This assay was developed and the performance characteristics were determined at ViraCor Laboratories. This test is performed in a CLIA certified laboratory. FDA approval is not required for the performance of this test.

AS06-0108